Results 1 to 10 of about 750,934 (136)
Advanced Biology, 2021 AbstractT cell activation is a fine‐tuned process that involves T cell receptor and costimulation signals. To prevent undue activation of T cells, inhibitory molecules including PD‐1 (programmed death 1) are induced and function as brakes for T cell signaling.
Qi Wang +3 more
openaire +2 more sources
Revisiting the PD-1 pathway [PDF]
Science Advances, 2020 This review provides an overview of recent advances in understanding the interactions and signaling of PD-1 and its ligands.
Nikolaos Patsoukis +3 more
openaire +2 more sources
Monitoring PD-1 Phosphorylation to Evaluate PD-1 Signaling during Antitumor Immune Responses [PDF]
Cancer Immunology Research, 2021 Abstract PD-1 expression marks activated T cells susceptible to PD-1–mediated inhibition but not whether a PD-1–mediated signal is being delivered. Molecular predictors of response to PD-1 immune checkpoint blockade (ICB) are needed.
Xia Bu +14 more
openaire +2 more sources
PD-1 and PD-1 ligands: from discovery to clinical application [PDF]
International Immunology, 2007 Programmed cell death-1 (PD-1, Pdcd1), an immunoreceptor belonging to the CD28/CTLA-4 family negatively regulates antigen receptor signaling by recruiting protein tyrosine phosphatase, SHP-2 upon interacting with either of two ligands, PD-L1 or PD-L2.
Taku, Okazaki, Tasuku, Honjo
openaire +2 more sources
PD-1, gender, and autoimmunity [PDF]
Autoimmunity Reviews, 2010 Programmed death 1 (PD-1) and its ligands (PD-L1 and PD-L2) are responsible for inhibitory T cell signaling that helps mediate the mechanisms of tolerance and immune homeostasis. The PD-1:PD-L signaling pathway has been shown to play an important role in a variety of diseases, including autoimmune conditions, chronic infection, and cancer.
Ravi K, Dinesh +2 more
openaire +2 more sources
Current Opinion in Pharmacology, 2015 Tumors may adopt normal physiologic checkpoints for immunomodulation leading to an imbalance between tumor growth and host surveillance. Antibodies targeting the PD-1/PD-L1 checkpoint have shown dynamic and durable tumor regressions, suggesting a rebalancing of the host-tumor interaction.
Joel, Sunshine, Janis M, Taube
openaire +2 more sources
Critical Care, 2016 Increasing evidence suggests that after the first pro-inflammatory hours, sepsis is characterized by the occurrence of severe immunosuppression. Several mechanisms have been reported to participate in sepsis-induced immune alterations affecting both innate and adaptive immunity.
Monneret, Guillaume +2 more
openaire +3 more sources
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas [PDF]
Blood, 2018 Programmed cell death protein 1 (PD-1) blockade targeting the PD-1 immune checkpoint has demonstrated unprecedented clinical efficacy in the treatment of advanced cancers including hematologic malignancies. This article reviews the landscape of PD-1/programmed death-ligand 1 (PD-L1) expression and current PD-1 blockade immunotherapy trials in B-cell ...
Xu-Monette, Zijun Y +2 more
openaire +2 more sources
Anti-PD-1-Induced Hidradenitis Suppurativa [PDF]
Dermatopathology, 2021 Mucocutaneous adverse events are commonly observed under immune checkpoint inhibitors (ICIs) therapy. Here, we report the case of a 43-year-old male patient with a stage IIIC melanoma disease who developed hidradenitis suppurativa (HS) three months after the beginning of an anti-PD-1 (nivolumab) adjuvant therapy.
Maillard, Alexia +2 more
openaire +4 more sources
Reinvigorating exhausted HIV-specific T cells via PD-1–PD-1 ligand blockade [PDF]
The Journal of Experimental Medicine, 2006 The programmed death (PD)-1–PD-1 ligand (PD-L) pathway, which is part of the B7–CD28 family, consists of the PD-1 receptor and its two ligands PD-L1 and PD-L2. Engagement of PD-1 by its ligands inhibits immune responses, and recent work has shown that PD-1 is highly expressed on exhausted T cells during chronic lymphocytic choriomeningitis virus (LCMV)
Freeman, Gordon J. +3 more
openaire +2 more sources